Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer
In patients who had a D2 gastrectomy, perioperative administration of the oral fluoropyrimidine derivative S-1 and oxaliplatin yielded better outcomes than adjuvant capecitabine and oxaliplatin in a phase 3 trial.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Trial to test if cannabis-based mouth spray can treat brain tumours
First such study in the world aims to find out if Sativex combined with chemotherapy can help treat glioblastomaCancer charities and the NHS are preparing to investigate whether a cannabis-based mouth spray can treat brain tumours and help patients to live longer.Doctors will give patients across the UK with a recurrent brain tumour called a glioblastoma the drug, which is known as Sativex, alongside a chemotherapy medication – temozolomide – in a clinical trial in an attempt to kill off cancerous cells.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 3, 2021 Category: Science Authors: Denis Campbell Health policy editor Tags: Cancer Cancer research UK news Medical research Health Science Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia
(Ohio State University Wexner Medical Center) The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Can turmeric reduce joint pain during breast cancer treatment?
(University of California - Davis Health) The UC Davis Comprehensive Cancer Center received a $50,000 grant from the Safeway Foundation. The funding will allow researcher Mili Arora to study whether the spice turmeric can provide pain relief for breast cancer patients on oral anti-estrogen drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news

New WHO study links moderate alcohol use with higher cancer risk
(Centre for Addiction and Mental Health) A new study from the World Health Organization's (WHO) International Agency for Research on Cancer (IARC), published in the journal Lancet Oncology, has found an association between alcohol and a substantially higher risk of several forms of cancer, including breast, colon, and oral cancers. Increased risk was evident even among light to moderate drinkers (up to two drinks a day), who represented 1 in 7 of all new cancers in 2020 and more than 100,000 cases worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2021 Category: International Medicine & Public Health Source Type: news

PPIs Could Be Bad News for Oral Cancer Therapies PPIs Could Be Bad News for Oral Cancer Therapies
GIs may want to be mindful of prescribing PPIs for patients with cancer because they may adversely affect concomitant oral therapies.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 13, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Oral Contraceptives Lower Ovarian Cancer Risk in BRCA Carriers
Findings seen in BRCA1 and BRCA2 mutation carriers; reduction greater with longer duration of use in BRCA1 carriers (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 7, 2021 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news

Oral Contraceptives Lower Ovarian Cancer Risk in BRCA Carriers
WEDNESDAY, July 7, 2021 -- Oral contraceptive use is associated with a reduced risk for ovarian cancer for BRCA mutation carriers, according to a study published in the July issue of the American Journal of Obstetrics& Gynecology. Lieske H.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 7, 2021 Category: Pharmaceuticals Source Type: news

NIDCR Science News - July 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. Mimicking Mother Nature to Grow a Gland New video shows how scientists achieved first key step in growing an artificial salivary gland NIDCR • July 2, 2021 A Four-Decade Quest to Uncover a Molecular Secret Scientist's lifelong research could hold clues to brain disorders, cancer NIDCR • June 21, 2...
Source: NIDCR Science News - July 6, 2021 Category: Dentistry Source Type: news

Cancer symptoms: Three visible signs of a tumour on the tongue
CANCER cells can multiply in any part of your body, including your mouth. Would you know what to look out for if you said "ahh" in front of the mirror? (Source: Daily Express - Health)
Source: Daily Express - Health - July 3, 2021 Category: Consumer Health News Source Type: news

Oncotarget: Loss of CPAP in oral cancer
(Impact Journals LLC) CPAP also plays a vital role in suppressing tumorigenesis in OSCC by facilitating EGFR homeostasis (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 2, 2021 Category: Cancer & Oncology Source Type: news

NIDCR's Summer 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Summer 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR to Release Report on Oral Health in America As a 20-year follow-up to the seminal Oral Health in America: A Report of the Surgeon General, NIDCR will release Oral Health in America: Advances and Challenges in the fall of 2021. The report will illuminate new directions...
Source: NIDCR Science News - July 1, 2021 Category: Dentistry Source Type: news

Jessica Morris obituary
Campaigner for better treatments for people with brain cancerThe communications consultant Jessica Morris did much to give a voice to people who lacked one. In the years up to her death at the age of 57 from brain cancer, she made her illness the basis of a campaign to find treatments for others.In January 2016 she was hiking in a valley north of New York when she found herself trying to speak: “Sounds came out of my mouth, but they weren’t words,” she said later. That seizure led to a diagnosis of glioblastoma (GBM), the most aggressive form of brain cancer, for which the median survival rate is 14 month...
Source: Guardian Unlimited Science - June 30, 2021 Category: Science Authors: Gaby Wood Tags: Cancer Cancer research Charities Voluntary sector Media Health Society Medical research Science UK news US news World news Source Type: news

Heart Failure Linked to Increased Incidence of Cancer
Increased rates of cancer seen among women and men and for cancer at multiple sites, including lip, oral cavity, pharynx, respiratory organs (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 29, 2021 Category: Cancer & Oncology Tags: Cardiology, Dermatology, Gastroenterology, Gynecology, Internal Medicine, Oncology, ENT, Pulmonology, Urology, Conference News, Source Type: news

Photobiomodulation: Evaluation in Various Specialties Underway Photobiomodulation: Evaluation in Various Specialties Underway
The therapy is used to treat a wide variety disorders including acne vulgaris, psoriasis, burns, wound healing, and oral mucositis associated with cancer treatment.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 18, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves relugolix for advanced prostate cancer
On December 18, 2020, the Food and Drug Administration approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, (ORGOVYX, Myovant Sciences, Inc.) for adult patients with advanced prostate cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Patients to Get Oral Cancer Meds Within 72 Hours Under New Bill Patients to Get Oral Cancer Meds Within 72 Hours Under New Bill
The TACT Act, a bipartisan bill that was recently introduced into Congress, would guarantee that cancer patients get their prescribed oral cancer medications within 72 hours.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

What Are Some Indications for Using Dexamethasone?
Discussion Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Roche presents data on giredestrant, a next generation selective oestrogen receptor degrader for people with hormone receptor-positive, HER-2 negative breast cancer
Basel, 4 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the presentation of new and updated data on giredestrant (formerly known as GDC-9545), an investigational next generation oral selective oestrogen receptor degrader (SERD), in people with hormone receptor (HR)-positive, HER2-negative breast cancer. Breast cancer is now the most common cancer in the world, with HR-positive being the most common subtype representing 70% of cases.1,2 Data from these studies will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2021.“We’re encour...
Source: Roche Investor Update - June 4, 2021 Category: Pharmaceuticals Source Type: news

US Oncology Research, The US Oncology Network and Ontada Announce Clinical Data Showcased in Plenary and Oral Sessions at ASCO Annual Meeting
THE WOODLANDS, Texas, June 3, 2021 — US Oncology Research, The US Oncology Network (The Network), and OntadaTM announce they contributed to more than 75 studies covering topics including gynecologic cancer, lung cancer and immunotherapy which will be presented at the upcoming 2021 American Society o... (Source: McKesson News)
Source: McKesson News - June 3, 2021 Category: Information Technology Source Type: news

Mayo Clinic study provides clarity on use of anticoagulants in gastrointestinal cancers
(Mayo Clinic) ROCHESTER, Minn. -- A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers. The findings were published Wednesday, June 2, in Mayo Clinic Proceedings. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic study provides clarity on use of anticoagulants in gastrointestinal cancers
ROCHESTER, Minn. -- A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers. The findings were published Wednesday, June 2, in Mayo Clinic Proceedings. Among the study's findings: Rivaroxaban showed no higher risk [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 3, 2021 Category: Hospital Management Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The metabolic and molecular regulation of physical activity and nutrition in skeletal muscle, in relation to ageing
Increases in muscle protein synthesis (MPS) and decreases in muscle protein breakdown (MPB) associated with food-intake are fundamental processes underlying day-to-day skeletal muscle maintenance. Increasing circulatory essential amino acids (EAA) through oral intake/I.V infusions of free-amino acids, or ingestion of dietary proteins, stimulates skeletal muscle anabolism. Yet, crucially, while physical activity enhances anabolic responses to nutrition; inactivity and chronological ageing impair them. It is crucial in the many scenarios of muscle wasting (e.g. cancer, ageing, organ failure, trauma), nutrition/physical activ...
Source: The Nutrition Society - June 1, 2021 Category: Nutrition Authors: Lulu Yacob Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlight...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Study finds major anti-inflammatory immune activity that favors oral cancer tumors
(MELISA Institute) This collaborative research made significant progress in the understanding of molecular mechanisms preventing an effective antitumor immune response in oral cancer; the latter due to the production of chemical mediators that induce an anti-inflammatory regulatory response that favors tumor development through a vitamin D signaling pathway. The study was published in Frontiers in Immunology on May 7, 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

BridgeBio's lean focus on genetic drivers scores 2nd drug approval in 3 months
The newest oral drug will cost about $21,500 per month to tackle one of the most aggressive forms of cancer. But the company also expects mid-stage clinical results later this year for the same drug as a treatment for a form of dwarfism. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 28, 2021 Category: American Health Authors: Ron Leuty Source Type: news

BridgeBio's lean focus on genetic drivers scores 2nd drug approval in 3 months
The newest oral drug will cost about $21,500 per month to tackle one of the most aggressive forms of cancer. But the company also expects mid-stage clinical results later this year for the same drug as a treatment for a form of dwarfism. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 28, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

BridgeBio's lean focus on genetic drivers scores 2nd drug approval in 3 months
The newest oral drug will cost about $21,500 per month to tackle one of the most aggressive forms of cancer. But the company also expects mid-stage clinical results later this year for the same drug as a treatment for a form of dwarfism. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 28, 2021 Category: American Health Authors: Ron Leuty Source Type: news

BridgeBio's lean focus on genetic drivers scores 2nd drug approval in 3 months
The newest oral drug will cost about $21,500 per month to tackle one of the most aggressive forms of cancer. But the company also expects mid-stage clinical results later this year for the same drug as a treatment for a form of dwarfism. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 28, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

AI helps predict treatment outcomes for patients with diseased dental implants
 ANN ARBOR —Peri-implantitis, a condition where tissue and bone around dental implants becomes infected, besets roughly one-quarter of dental implant patients, and currently there's no reliable way to assess how patients will respond to treatment of this condition. To that end, a team led by the University of Michigan School of Dentistry developed a machine learning algorithm, a form of artificial intelligence, to assess an individual patient's risk of regenerative outcomes after surgical treatments of peri-implantitis.   The algorithm is called FARDEEP, which stands for Fast and Robust Decon...
Source: Dental Technology Blog - May 24, 2021 Category: Dentistry Source Type: news

Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 24, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today follow-up data from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of the investigational product talquetamab, the only off-the-shelf T-cell redirecting bispecific antibody in clinical development to target both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells (NCT03399799).[1],[2],[3] With a median follow-up of more than six months, updated results in 30 patients with relapsed or refractory multiple myeloma treated with talquetamab by subcutaneous (SC) administration at the recommend...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen ’s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
We reported initial findings for teclistamab at ASCO 2020, and study updates have observed a deepening of responses that have shown to be durable in a significant percentage of patients with relapsed or refractory multiple myeloma,” said Amrita Y. Krishnan, M.D., Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and Chief, Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, and study investigator. “Teclistamab exposure was sustained across the dosing interval and exceeded target levels, and consistent T-cell activation was ob...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Dental school researcher gets approval to begin clinical trials for cancer therapy
(Rutgers University) A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received US Food and Drug Administration (FDA) approval to treat cancer patients with a therapy based on Kachlany's discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib.[1] These data, which will be presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

NHS dentistry and oral health bulletin
The latest edition of the NHS dentistry and oral health bulletin has been published, in which chief dental officer Sara Hurley and Peter Johnson, NHS England ’s national clinical director for cancer, bring together useful resources and advice for dental professionals on mouth cancer. (Source: NHS Networks)
Source: NHS Networks - May 13, 2021 Category: UK Health Source Type: news

Latest Trends in the Management of Pulmonary Embolism Latest Trends in the Management of Pulmonary Embolism
Following clinical management of cancer-associated VTE in the hospital, direct oral anticoagulant therapy at discharge is your starting point, except in cases of intact luminal cancers.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 11, 2021 Category: Intensive Care Tags: Hospital Medicine News Source Type: news

New ultrasound technique detects fetal circulation problems
Researchers have developed a new ultrasound technique to monitor the placent...Read more on AuntMinnie.comRelated Reading: X-ray, CT reveal mummified ancient Egyptian was pregnant Fetal cardiovascular MRI helps diagnose congenital heart defects Lung ultrasound spots COVID-19 in newborns Pregnancy is safe for breast cancer survivors Imaging detects big, rare tumor protruding from fetus's mouth (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 11, 2021 Category: Radiology Source Type: news

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Media News - May 11, 2021 Category: Pharmaceuticals Source Type: news

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Investor Update - May 11, 2021 Category: Pharmaceuticals Source Type: news

Secondhand Smoke Exposure Tied to Oral Cancer Risk Secondhand Smoke Exposure Tied to Oral Cancer Risk
People who are exposed to secondhand smoke are more likely to develop oral cancers than their counterparts who don't have this exposure, a systematic review and meta-analysis suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 10, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Gut health startup Viome gets breakthrough device designation for mRNA analysis tool
Viome has adapted its technology to search for the presence of oral squamous cell carcinoma and oropharyngeal cancer in users ’ saliva samples.    (Source: mobihealthnews)
Source: mobihealthnews - May 7, 2021 Category: Information Technology Source Type: news

High-Dose Vitamin D Supplements Significantly Reduce ICU Admissions & COVID-19 Deaths
Conclusion Vitamin D, 200,000 IU dose in single or divided doses is safe and highly cost-effective in reducing complications and deaths in persons with SARS-CoV-2 infection. Early use of vitamin D (100,000 to 600,000 IU) can reduce ICU admissions by ~80%. Therefore, vitamin D can greatly reduce the need for expanding ICU beds AND cost less than 0.001% of using an ICU bed/day. Additional information regarding bolus D3 and oral calcifediol: There is little vitamin D3 (cholecalciferol) in food and multivitamins, including fortified food. Without passing through glass or sunscreen, skin exposure to ultraviolet-B from high-elev...
Source: IPS Inter Press Service - Health - May 6, 2021 Category: International Medicine & Public Health Authors: Sunil J. Wimalawansa Tags: Featured Global Headlines Health Human Rights Humanitarian Emergencies Sustainability TerraViva United Nations Source Type: news